SEC Form 4 · accession 0001548538-19-000002
Inspire Medical Systems, Inc. · INSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Casey M Tansey
Director
Period of report
Mar 6, 2019
Accepted (ET)
Mar 7, 2019 · 9:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609550
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 6, 2019 | J | 22,923 | — | A | 224,603 | D | |
| Common StockF1,F2 | Mar 6, 2019 | J | 1,084,127 | — | D | 0 | I | Directly owned by USVP IX |
| Common StockF3 | Mar 7, 2019 | S | 25,000 | $54.7758 | D | 199,603 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
- F2The shares are directly held by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.83 to $55.66, inclusive for sales made on March 7, 2019. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.